Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists.

What Was Tested

Researchers studied Glucagon in this observational study publication.

However, the impact of GLP-1RAs therapy on cardiorenal outcomes of diabetic patients at the commencement of dialysis remains unexplored.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A cohort of type 2 diabetic patients initializing dialysis was identified from the TriNetX global database.

Patients treated with GLP-1RAs and those treated with long-acting insulin (LAI) were matched by propensity score.

How the Study Was Run

The researchers focused on all-cause mortality, four-point major adverse cardiovascular events (4p-MACE), and major adverse kidney events (MAKE).

What Was Measured

However, the impact of GLP-1RAs therapy on cardiorenal outcomes of diabetic patients at the commencement of dialysis remains unexplored.

Topics PubMed links to this paper include Biomarkers, Cardiovascular Diseases, Cause of Death, Databases, Factual, Diabetes Mellitus, Type 2, Diabetic Nephropathies and Glucagon-Like Peptide-1 Receptor Agonists.

The authors tagged it with the keywords Acute kidney injury, GLP-1, Major adverse cardiac events, Major adverse kidney events, Mortality and Renal replacement therapy.

What This Means in Plain Language

This is an observational study of Glucagon in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Cardiovascular diabetology), a journal based in England.

More context: the Glucagon compound page, all human trials.